$CRYM
Cryomass Technologies, Inc. Stock $crym

$crym Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023022859 Filed on March 24, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue		$0.00
YoY Change
Cost Of Revenue		$0.00
YoY Change
Gross Profit		$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$640.0K	$4.948M	$8.125M
YoY Change	-63.5%	359.17%	71.38%
% of Gross Profit
Research & Development	$123.00	$0.00	$20.52K
YoY Change	-99.28%
% of Gross Profit
Depreciation & Amortization	$10.13K	$91.50K	$5.400K
YoY Change	-53.6%	319.15%	-87.63%
% of Gross Profit
Operating Expenses	$1.532M	$5.514M	$10.31M
YoY Change	-28.02%	139.51%	29.03%
Operating Profit	-$1.532M	-$5.514M	-$10.31M
YoY Change	-28.02%	139.51%	29.03%
Interest Expense	$53.66K	-$119.4K	$147.0K
YoY Change	-318.94%	-88.48%	-106.86%
% of Operating Profit
Other Income/Expense, Net	-$66.97K		-$132.7K
YoY Change	173.18%		-93.81%
Pretax Income	-$1.600M	-$5.633M	-$10.44M
YoY Change	-25.66%	68.72%	3.06%
Income Tax		-$21.79K	-$21.79K
% Of Pretax Income
Net Earnings	-$1.599M	-$5.612M	-$10.42M
YoY Change	-25.73%	-15.86%	-18.95%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01		-$0.05
Diluted Earnings Per Share	-$0.01	-$0.03	-$0.05
COMMON SHARES
Basic Shares Outstanding	204.2M shares	202.5M shares	200.9M shares
Diluted Shares Outstanding	204.0M shares		200.9M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$664.0K	$2.016M	$2.016M
YoY Change	-81.53%	-65.08%	-65.08%
Cash & Equivalents	$664.0K	$2.016M
Short-Term Investments
Other Short-Term Assets	$114.6K	$150.4K	$150.4K
YoY Change	56.55%	-80.14%	-80.14%
Inventory
Prepaid Expenses	$92.77K	$128.7K
Receivables
Other Receivables
Total Short-Term Assets	$778.5K	$2.166M	$2.167M
YoY Change	-78.77%	-66.82%	-66.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$737.3K	$525.9K	$525.9K
YoY Change	215.57%	133.71%	133.72%
Goodwill	$1.190M	$1.190M
YoY Change		0.0%
Intangibles		$3.981M
YoY Change
Long-Term Investments		$10.30M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$5.807M	$5.696M	$5.696M
YoY Change	-39.88%	-37.08%	-37.08%
TOTAL ASSETS
Total Short-Term Assets	$778.5K	$2.166M	$2.167M
Total Long-Term Assets	$5.807M	$5.696M	$5.696M
Total Assets	$6.586M	$7.863M	$7.863M
YoY Change	-50.58%	-49.54%	-49.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.431M	$1.288M	$1.288M
YoY Change	4.86%	-31.52%	-31.52%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.431M	$1.288M	$1.288M
YoY Change	4.86%	-31.55%	-31.55%
LONG-TERM LIABILITIES
Long-Term Debt	$2.000M	$2.000M	$2.000M
YoY Change	860.02%	1029.43%	1029.43%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$2.000M	$2.000M	$2.000M
YoY Change	860.02%	1029.43%	1029.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.431M	$1.288M	$1.288M
Total Long-Term Liabilities	$2.000M	$2.000M	$2.000M
Total Liabilities	$3.431M	$3.288M	$3.288M
YoY Change	118.1%	59.67%	59.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$40.61M	-$39.01M
YoY Change		36.46%
Common Stock	$204.8K	$202.7K
YoY Change		2.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.155M	$4.574M	$4.574M
YoY Change
Total Liabilities & Shareholders Equity	$6.586M	$7.863M	$7.863M
YoY Change	-50.58%	-49.54%	-49.54%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.599M	-$5.612M	-$10.42M
YoY Change	-25.73%	-15.86%	-18.95%
Depreciation, Depletion And Amortization	$10.13K	$91.50K	$5.400K
YoY Change	-53.6%	319.15%	-87.63%
Cash From Operating Activities	-$1.338M	-$913.5K	-$4.767M
YoY Change	-17.96%	-63.9%	-14.89%
INVESTING ACTIVITIES
Capital Expenditures	$13.74K	$222.1K	$300.9K
YoY Change	-259.03%	-346.74%	-233.71%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$618.8K
YoY Change	-100.0%	-100.0%	-76.0%
Cash From Investing Activities	-$13.74K	-$222.1K	-$1.019M
YoY Change	-97.81%	58.63%	-63.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$256.9K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		21.87K	$2.029M
YoY Change		-99.73%	-85.35%
NET CHANGE
Cash From Operating Activities	-$1.338M	-913.5K	-$4.767M
Cash From Investing Activities	-$13.74K	-222.1K	-$1.019M
Cash From Financing Activities		21.87K	$2.029M
Net Change In Cash	-$1.352M	-1.114M	-$3.757M
YoY Change	-37.94%	-120.12%	-169.02%
FREE CASH FLOW
Cash From Operating Activities	-$1.338M	-$913.5K	-$4.767M
Capital Expenditures	$13.74K	$222.1K	$300.9K
Free Cash Flow	-$1.352M	-$1.136M	-$5.068M
YoY Change	-16.67%	-53.47%	-5.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-56155
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5051728
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1001 Bannock Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 612
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Denver
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80204
CY2022	dei	City Area Code CityAreaCode	303
CY2022	dei	Local Phone Number LocalPhoneNumber	416-7208
CY2022	dei	Entity Registrant Name EntityRegistrantName	CRYOMASS TECHNOLOGIES INC.
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	38287902	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	204216637	shares
CY2022	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2022	dei	Auditor Firm AuditorFirmId	5041
CY2022	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2016057	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5772839	usd
CY2022Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	21788	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	128651	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	757383	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2166496	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	6530222	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent	3600000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525855	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	225000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1190000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	1190000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3980582	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4038600	usd
CY2022Q4	us-gaap	Assets Assets	7862933	usd
CY2021Q4	us-gaap	Assets Assets	15583822	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1288465	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1882419	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1288465	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1882419	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	2000000	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	177083	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3288465	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2059502	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	202651205	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	202651205	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	196949801	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	196949801	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	202652	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	196950	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43163579	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	41916207	usd
CY2022Q4	crym	Common Stock To Be Issued CommonStockToBeIssued	219765	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39011528	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28588837	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4574468	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	13524320	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7862933	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15583822	usd
CY2022	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2003506	usd
CY2021	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	3207110	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5600038	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3983226	usd
CY2022	us-gaap	Legal Fees LegalFees	2525347	usd
CY2021	us-gaap	Legal Fees LegalFees	757828	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20518	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	162401	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	43663	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	10311810	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	7991827	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10311810	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-7991827	usd
CY2022	us-gaap	Interest Expense InterestExpense	147014	usd
CY2021	us-gaap	Interest Expense InterestExpense	2189959	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	14345	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	47144	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-132669	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2142815	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10444479	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10134642	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21788	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10422691	usd
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10134642	usd
CY2022	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	3021724	usd
CY2021	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	3021724	usd
CY2021	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	2725001	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-10422691	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-12859643	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10422691	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12859643	usd
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.06
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	200884333	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	157509715	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	3605294	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9511025	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1804500	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	900702	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	5408403	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	968012	usd
CY2021	crym	Share Issuance For Interest Payment On Note Payable ShareIssuanceForInterestPaymentOnNotePayable	49941	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	784364	usd
CY2021	crym	Stockbased Compensation Options StockbasedCompensationOptions	968205	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	515763	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1867754	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12859643	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	13524320	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	612500	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	603463	usd
CY2022	crym	Shares Issued From Warrants Exercised SharesIssuedFromWarrantsExercised	66151	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	214134	usd
CY2022	crym	Share Cancellation Related To Interest On Not Payable ShareCancellationRelatedToInterestOnNotPayable	-23409	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10422691	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4574468	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10422691	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10134642	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	72917	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1547181	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	157001	usd
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	43663	usd
CY2022	crym	Bad Debt Expenses BadDebtExpenses	4218831	usd
CY2021	crym	Bad Debt Expenses BadDebtExpenses	540000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	590625	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1011075	usd
CY2021	us-gaap	Provision For Other Losses ProvisionForOtherLosses	318970	usd
CY2022	crym	Stockbased Compensation Expense StockbasedCompensationExpense	603463	usd
CY2021	crym	Stockbased Compensation Expense StockbasedCompensationExpense	2653271	usd
CY2022	crym	Deferred Income Tax Expense DeferredIncomeTaxExpense	21788	usd
CY2021	crym	Deferred Income Tax Expense DeferredIncomeTaxExpense	14926	usd
CY2022	crym	Prepaid Expenses PrepaidExpenses	-628732	usd
CY2021	crym	Prepaid Expenses PrepaidExpenses	696908	usd
CY2022	crym	Accounts Payable And Accrued Expenses AccountsPayableAndAccruedExpenses	593954	usd
CY2021	crym	Accounts Payable And Accrued Expenses AccountsPayableAndAccruedExpenses	366587	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4766864	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5098903	usd
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-501609	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4766864	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5600512	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1000000	usd
CY2021	crym	Payoff Of Cryo Cann Loan Agreement At Closing PayoffOfCryoCannLoanAgreementAtClosing	1247684	usd
CY2022	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	618831	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	300855	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	225000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	98983	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1018669	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2472684	usd
CY2021	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-330560	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1018669	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2803244	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	237590	usd
CY2021	crym	Repayment Of Notes Payable Related Parties RepaymentOfNotesPayableRelatedParties	237590	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	256876	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10308000	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	21875	usd
CY2021	us-gaap	Proceeds From Construction Loans Payable ProceedsFromConstructionLoansPayable	286441	usd
CY2021	crym	Repaymentofloanspayablecurrent Repaymentofloanspayablecurrent	-698800	usd
CY2022	crym	Proceeds From Notes Payable Current ProceedsFromNotesPayableCurrent	1750000	usd
CY2021	crym	Proceeds From Notes Payable Current ProceedsFromNotesPayableCurrent	4900000	usd
CY2021	crym	Repayment Of Seller Note For Acquisition RepaymentOfSellerNoteForAcquisition	1173016	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	281771	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2028751	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	13340854	usd
CY2021	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	505902	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2028751	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13846756	usd
CY2022	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-3756782	usd
CY2021	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	5769267	usd
CY2021	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-326267	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5772839	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	329839	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2016057	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5772839	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	16592	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	449068	usd
CY2022	crym	Common Stock Issued Pursuant To Vesting Of Restricted Stock Units CommonStockIssuedPursuantToVestingOfRestrictedStockUnits	1168600	usd
CY2021	crym	Common Stock Issued Pursuant To Vesting Of Restricted Stock Units CommonStockIssuedPursuantToVestingOfRestrictedStockUnits	2851103	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. NATURE OF THE BUSINESS</b> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cryomass Technologies Inc (“Cryomass Technologies” or the “Company”) designs, manufactures and is developing the strategy to commercialize patented cryo-mechanical systems for the harvesting and refinement of hemp, cannabis, and potentially other high value crops such as hops. The system exploits CryoMass’s U.S.-patented process for the controlled application of liquid nitrogen to stabilize and separate the structural elements of gross plant material. The device currently under development can be operated at a cultivation site or be installed at a processing facility and is being optimized for the collection of fully intact hemp and cannabis trichomes. The first functional “beta” machine has completed field testing. The Company recently signed a license and lease arrangement with a third party to deploy multiple CryoMass trichome separation units at the prospective partner’s facility in California and other locations, with the intention of starting commercial operations shortly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s principal office is located at 1001 Bannock St., Suite 612, Denver, CO 80204, and its telephone number is 303-416-7208. The Company’s website is www.cryomass.com. Information appearing on the website is not incorporated by reference into this prospectus.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company over its history has explored a number of different business opportunities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 10, 2018, the Company began to establish various business ventures in Colombia through its Colombian subsidiary, First Colombia Devco S.A.S (“Devco”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 1, 2019, the Company acquired 100% of the membership interests in General Extract, LLC, a Colorado limited liability company, in exchange for the shares of Devco. The name of this subsidiary was subsequently changed to Cryomass LLC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 15, 2019, the Company entered into a Membership Interest Purchase Agreement to acquire cannabis-related intellectual property and certain other assets, but not cannabis licenses, of Critical Mass Industries LLC (“CMI”), a Colorado limited liability company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective December 31, 2021, the Company disposed of all CMI-related assets and extinguished any and all related obligations. Therefore, we determined that CMI no longer qualifies as a variable interest entity (“VIE”) as of December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the Company established a wholly owned Colombian subsidiary, Andina Gold Colombia SAS for this purpose acquiring gold properties in Colombia. However, due to the untimely death of our top geologist, the Company determined that pursuit of gold exploration in Colombia was no longer a practical alternative. In Q1 2022 the respective subsidiary was closed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 22, 2021, the Company entered into an Asset Purchase Agreement with Cryocann USA Corp, a California corporation (“Cryocann”), pursuant to which Company acquired substantially all the assets of Cryocann. The aggregate purchase price was $3,500,000 million in cash and 10,000,000 shares of Company common stock As part of the Cryocann Acquisition, we retained both Cryocann employees, who have expert knowledge of the industry, related participants, customers and the acquired patented technology. Under their employment agreements, each employee may receive compensation if specific performance targets are met in association with our future operating performance when the Cryocann technology enters the market. The technology and assets acquired from Cryocann are operated from the Company’s subsidiary, Cryomass LLC. The patented cryo-mechanical technology is for the separation of plant materials in the harvesting of hemp and cannabis, and potentially other high value crops such as hops. We believe this technology will reduce processing costs and increases the quality of extracted compounds. We are exploring the application of the underlying technology to a broad range of industries that handle high-value materials and that could benefit from our precision capture methods. We anticipate that cannabis and hemp will be the first in a series of such industries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To develop and commercialize the technology, we contracted with an independent engineering and manufacturing firm to refine the design of our cryo-mechanical system for the handling of harvested hemp, cannabis and other high-value plants. The system exploits CryoMass’s U.S.-patented process for the controlled application of liquid nitrogen to stabilize and separate the structural elements of gross plant material. The device currently under development is scaled for highway transportability and is being optimized for the low-cost collection of fully intact hemp and cannabis trichomes. It can be used within minutes after plants have been cut and can also efficiently capture trichomes from fresh frozen or even dried plant parts, including trim. The device’s through-put capacity is expected to be approximately 600 kilograms of gross plant material per hour. The advanced design for the equipment has been completed, and testing of a prototype machine is currently underway. The engineering and manufacturing firm has indicated that it has the capacity to build 10 to 15 such devices per month.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first functional “beta” machine has completed field testing. The Company recently signed a license and lease arrangement with a third party to deploy multiple CryoMass trichome separation units at the prospective partner’s facility in California and other locations, with the intention of starting commercial operations shortly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes the CryoMass system will deliver a compelling combination of cost and time savings while enhancing product quality and quantity for largescale cultivators and processors of hemp and cannabis. The use of a CryoMass system – which can be trucked to and operated on the fields of most large hemp and cannabis growers or be permanently installed at a user’s processing facility – should eliminate many of the costs that come with traditional practices, especially the labor, fuel and capital costs of drying and curing hemp or cannabis that is grown for the extraction of end products. With traditional practices, harvested plants are transported to a specially constructed drying house and then treated for a week or longer under controlled conditions of temperature and humidity. It’s a costly method. With our system, harvested plants are simply fed into the front end of a CryoMass machine, and minutes later fully intact trichomes are collected at the back end of the machine. With traditional practices and their seven-to-ten days of handling and drying, a large share of a plant’s valuable trichomes break off and are lost. Then the remaining trichomes are damaged by long exposure to oxygen and by the evaporation of their volatile terpenes. The CryoMass system, on the other hand, stabilizes and collects fully intact trichomes at harvest, leaving no opportunity for such wasteful loss. Field-captured trichomes are the cleanest element of a hemp or cannabis plant because, unlike the rest of the plant, trichomes do not readily take up heavy metals, pesticides or other common soil contaminants. As a product for end-users, field-captured trichomes are closest to being contaminant free. As feedstock for manufacturers of extracts and oils, they are the key to the purest products possible.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because the trichomes collected with CryoMass technology represent only 10% or so of a plant’s weight and volume, they are cheaper to ship and store than gross plant material. For the same reason and because trichomes are free of the waxes and other unwanted materials found in the rest of the plant, processing trichomes into oils and extracts can be far quicker, cheaper and easier than processing gross plant material. Even trichomes captured from dried or frozen plant parts deliver this cost-saving advantage to processors of oils and extracts. The three-dimensional advantage achievable with the CryoMass system – first-stage cost savings, product enhancement and downstream cost savings – can as much as double a crop’s wholesale value. And in some jurisdictions, users may enjoy a reduction in excise taxes levied on cannabis and hemp harvests, which typically are tied to the gross weight of hemp or cannabis that is removed from the field.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Production and processing of hemp and cannabis is a huge, worldwide industry. In the U.S., for example, the wholesale value of the cannabis crop from just the 11 states permitting adult-use and medical cannabis exceeds $6 billion annually. Growth in the U.S. and in the worldwide market is likely fed in part by the growing acceptance of medicinal cannabis products and anticipated legislative changes in various jurisdictions worldwide.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And that may only be chapter one of the Company’s story. Several other high-value plants, including species that are important for health and wellness products, wrap their valuable elements in trichomes. The technology we are developing for hemp and cannabis may have profitable application to those other species as well. We intend to find out.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September, we were granted an additional patent for our process from the Chinese Intellectual Property Office. We currently are taking steps to gain further protection for our intellectual property through the European Union Intellectual Property Office and several other international jurisdictions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17<sup>th</sup> we announced the completion of a $10.3 million equity financing. The financing and the earlier conversion of substantially all the company’s debt into common stock left the Company with a strong balance sheet and adequate resources for our planned business development during the coming twelve months. In connection with the financing, 1,010,000 shares and 760,000 shares of CryoMass Technologies common stock were purchased by CEO Christian Noël and Chairman of the Board Delon Human, respectively.</p>
CY2019Q3	crym	Membership Interests MembershipInterests	1	pure
CY2021Q2	crym	Aggregate Purchase Amount AggregatePurchaseAmount	3500000000000	usd
CY2021Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10000000	shares
CY2022	crym	Membership Interests MembershipInterests	0.10	pure
CY2022	us-gaap	Other Labor Related Expenses OtherLaborRelatedExpenses	6000000000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	10300000	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	1010000	shares
CY2021Q4	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	3600000	usd
CY2021	us-gaap	Variable Interest Entity Qualitative Or Quantitative Information Date Involvement Began1 VariableInterestEntityQualitativeOrQuantitativeInformationDateInvolvementBegan1	2023-12-31
CY2022Q4	crym	Working Capital WorkingCapital	878031	usd
CY2022Q4	us-gaap	Cash Cash	2016057	usd
CY2022	us-gaap	Retail Land Sales Estimated Cost Of Major Improvements RetailLandSalesEstimatedCostOfMajorImprovements	4000000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6600000	usd
CY2022	crym	Cash For Operating Activities CashForOperatingActivities	4766864	usd
CY2022	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	10422691	usd
CY2022Q4	crym	Accumulated Deficits AccumulatedDeficits	-39011528	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to determining the fair value of the assets acquired and liabilities assumed in acquisition, determining the useful lives and potential impairment of long-lived assets and potential impairment of goodwill. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reclassifications</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain items in the interim consolidated financial statements were reclassified from prior periods for presentation purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentrations of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts. Aside from this, the Company does not believe it is exposed to any unusual credit risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	crym	Income Taxes Description IncomeTaxesDescription	In accordance with ASC 740-10, for those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, our policy will be to record the largest amount of tax benefit that is more likely than not to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit will be recognized in the consolidated financial statements.
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	928779	usd
CY2022	crym	Conversion Of Warrants ConversionOfWarrants	515763	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	1444542	usd
CY2022	crym	Unvested Of Shares Restricted Stock Potentially Dilutive Securities Outstanding UnvestedOfSharesRestrictedStockPotentiallyDilutiveSecuritiesOutstanding	772273	shares
CY2021	crym	Unvested Of Shares Restricted Stock Potentially Dilutive Securities Outstanding UnvestedOfSharesRestrictedStockPotentiallyDilutiveSecuritiesOutstanding	2200003	shares
CY2021Q2	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	3500000000000	usd
CY2021Q2	us-gaap	Stock Issued During Period Shares Share Based Compensation Gross StockIssuedDuringPeriodSharesShareBasedCompensationGross	10000000	shares
CY2021Q4	crym	Promissory Note Issued PromissoryNoteIssued	1252316	usd
CY2021Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	2500000	usd
CY2021	us-gaap	Business Combination Separately Recognized Transactions Net Gains And Losses BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses	9209433	usd
CY2022Q3	crym	Loan Agreement LoanAgreement	2000000	usd
CY2021	us-gaap	Extinguishment Of Debt Gain Loss Per Share Net Of Tax ExtinguishmentOfDebtGainLossPerShareNetOfTax	0.05
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	7641737	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-10422691	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-12417483	usd
CY2022	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.05
CY2021	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.08
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	525855	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	225000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	531255	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	225000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5400	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	525855	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	225000	usd
CY2022	us-gaap	Depreciation Depreciation	5400	usd
CY2021	us-gaap	Depreciation Depreciation	0	usd
CY2022	crym	Carrying Value Of Goodwill CarryingValueOfGoodwill	1190000	usd
CY2021	crym	Carrying Value Of Goodwill CarryingValueOfGoodwill	1190000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4181246	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-200664	usd
CY2022Q4	crym	Amortized Intangible Assets Impairment AmortizedIntangibleAssetsImpairment	3980582	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4082263	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-43663	usd
CY2021Q4	crym	Amortized Intangible Assets Impairment AmortizedIntangibleAssetsImpairment	4038600	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	157001	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43663	usd
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	6600000	usd
CY2021	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	3600000	usd
CY2022Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	620000	usd
CY2021Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.936	pure
CY2021Q1	us-gaap	Debt Instrument Repurchase Date DebtInstrumentRepurchaseDate	2021-04-27
CY2021Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	225000	usd
CY2021Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.15	pure
CY2021Q1	us-gaap	Debt Instrument Repurchase Date DebtInstrumentRepurchaseDate	2021-05-07
CY2021Q3	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.12	pure
CY2021Q2	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.12	pure
CY2021Q3	crym	Loans Agreement LoansAgreement	300000	usd
CY2021Q3	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.9123	pure
CY2021Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-05-27
CY2021Q3	us-gaap	Debt Instrument Repurchase Date DebtInstrumentRepurchaseDate	2021-10-19
CY2022Q3	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.12	pure
CY2022	crym	Note Receivable Issued Amount NoteReceivableIssuedAmount	281771	usd
CY2021Q3	us-gaap	Derivative Liability Securities Sold Under Agreements To Resell Securities Loaned DerivativeLiabilitySecuritiesSoldUnderAgreementsToResellSecuritiesLoaned	237590	usd
CY2021Q4	crym	Note Interest NoteInterest	0.14	pure
CY2021Q4	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	250000	shares
CY2021Q4	us-gaap	Memberships In Exchanges Owned MembershipsInExchangesOwned	50000	usd
CY2022Q4	us-gaap	Derivative Liability Securities Sold Under Agreements To Resell Securities Loaned DerivativeLiabilitySecuritiesSoldUnderAgreementsToResellSecuritiesLoaned	2000000	usd
CY2022Q4	crym	Beneficial Percentage BeneficialPercentage	0.10	pure
CY2022Q4	crym	Note Interest NoteInterest	0.12	pure
CY2022Q4	us-gaap	Investment Maturity Date InvestmentMaturityDate	2024-10-01
CY2019Q3	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	72096	usd
CY2019	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	790000	shares
CY2019	us-gaap	Professional Fees ProfessionalFees	395000	usd
CY2021Q2	crym	Issuance Of Common Stock Shares IssuanceOfCommonStockShares	10000000	shares
CY2021Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	6903172	shares
CY2021Q2	crym	Agreements Shares AgreementsShares	2500000	shares
CY2021Q2	crym	Share Exchange For Services ShareExchangeForServices	633125	shares
CY2021Q3	crym	Common Stock Shares CommonStockShares	798414	shares
CY2021Q3	us-gaap	Stockholders Equity Note Changes In Capital Structure Subsequent Changes To Number Of Common Shares StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares	633707	shares
CY2021Q3	crym	Interest Rate InterestRate	92127	shares
CY2021Q4	crym	Common Stock Shares CommonStockShares	50700000	shares
CY2021Q4	crym	Common Stock In Exchange For Services CommonStockInExchangeForServices	1570501	shares
CY2021Q4	crym	Common Stock In Exchange For Extinguishment Of Debt CommonStockInExchangeForExtinguishmentOfDebt	24621119	shares
CY2022Q1	crym	Common Stock Shares CommonStockShares	458334	shares
CY2022Q1	crym	Common Stock In Exchange For Services CommonStockInExchangeForServices	550000	shares
CY2022Q1	crym	Common Stock For Director Compensation commonStockForDirectorCompensation	185529	shares
CY2022Q3	crym	Common Stock Shares CommonStockShares	416667	shares
CY2022Q3	crym	Common Stock In Exchange For Services CommonStockInExchangeForServices	1000000	shares
CY2022Q3	crym	Additionally Shares AdditionallyShares	92127	shares
	crym	Share Exchange For Services ShareExchangeForServices	125000	shares
CY2022Q4	crym	Share Based Compensation Arrangement By Share Based Restricted Stock Payment Award Number ShareBasedCompensationArrangementByShareBasedRestrictedStockPaymentAwardNumber	2200003	shares
CY2022Q4	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstandingNumber	0.45
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2064386	shares
CY2022	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Grant In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueGrantInPeriod	0.29
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	3442116	shares
CY2022	crym	Share Based Compensation Arrangement By Share Based Payment Award Option Vested Weighted Average Grants Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestedWeightedAverageGrantsDateFairValue	0.4
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	50000	shares
CY2022	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Averages Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAveragesGrantDateFairValue	0.17
CY2021Q4	crym	Share Based Compensation Arrangement By Share Based Restricted Stock Payment Award Number ShareBasedCompensationArrangementByShareBasedRestrictedStockPaymentAwardNumber	772273	shares
CY2021Q4	crym	Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstandingNumber	0.3
CY2022	crym	Fair Value Of Rs Us Vested FairValueOfRSUsVested	1168600	usd
CY2021	crym	Fair Value Of Rs Us Vested FairValueOfRSUsVested	2851102	usd
CY2022	crym	Unrecognized Stock Based Compensation UnrecognizedStockBasedCompensation	132747	usd
CY2021	crym	Unrecognized Stock Based Compensation UnrecognizedStockBasedCompensation	78676	usd
CY2022Q4	us-gaap	Shares Issued SharesIssued	0	shares
CY2021Q4	us-gaap	Shares Issued SharesIssued	5000000	shares
CY2022	crym	Total Fair Value TotalFairValue	0	usd
CY2021	crym	Total Fair Value TotalFairValue	968205	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	968205	usd
CY2021Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	73950000	shares
CY2021	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.4
CY2022	crym	Warrants warrants	220500	usd
CY2022	crym	Exercised Per Share exercisedPerShare	0.3
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2193341	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2202256	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-15527	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0015	pure
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	6511	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0006	pure
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-433010	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.0415	pure
CY2022Q4	crym	Deferred Tax Assets Nol Federal Pre2018 DeferredTaxAssetsNOLFederalPre2018	43367	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0	pure
CY2022	crym	Deferred Only Adjustment DeferredOnlyAdjustment	-360713	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0.0345	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0	pure
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2984005	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2857	pure
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1838803	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1753	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	367177	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.035	pure
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-3203	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0003	pure
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	10235	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001	pure
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	10235	usd
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001	pure
CY2022	crym	Stock Compensation StockCompensation	-122132	usd
CY2021	crym	Stock Compensation StockCompensation	7335	usd
CY2022	crym	Stock Compensation Options StockCompensationOptions	256288	usd
CY2021	crym	Stock Compensation Options StockCompensationOptions	259057	usd
CY2021Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	44384	usd
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	73637	usd
CY2021Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	8033	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	53747	usd
CY2021Q4	crym	Deferred Tax Assets Customer Relationships DeferredTaxAssetsCustomerRelationships	1947	usd
CY2021Q4	crym	Deferred Tax Assets Patent DeferredTaxAssetsPatent	3589	usd
CY2022Q4	crym	Deferred Tax Assets In Process Research Development Cryo Cann DeferredTaxAssetsInProcessResearchDevelopmentCryoCann	61490	usd
CY2021Q4	crym	Deferred Tax Assets In Process Research Development Cryo Cann DeferredTaxAssetsInProcessResearchDevelopmentCryoCann	26376	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	179892	usd
CY2022	crym	In Process Research Development Cmi InProcessResearchDevelopmentCMI	89619	usd
CY2021	crym	In Process Research Development Cmi InProcessResearchDevelopmentCMI	98135	usd
CY2022Q4	crym	Deferred Tax Assets Net Goodwill Cryo Cann DeferredTaxAssetsNetGoodwillCryoCann	-16862	usd
CY2021Q4	crym	Deferred Tax Assets Net Goodwill Cryo Cann DeferredTaxAssetsNetGoodwillCryoCann	3490	usd
CY2021Q4	crym	Deferred Tax Assets Nol Federal Pre2018 DeferredTaxAssetsNOLFederalPre2018	43367	usd
CY2022Q4	crym	Deferred Tax Assets Nol Federal Post2017 DeferredTaxAssetsNOLFederalPost2017	5233548	usd
CY2021Q4	crym	Deferred Tax Assets Nol Federal Post2017 DeferredTaxAssetsNOLFederalPost2017	2097542	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations		usd
CY2022	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation		usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Foreign Currency Translation Gains Losses DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses		usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Foreign Currency Translation Gains Losses DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses		usd
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.05
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.06
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
CY2022Q4	crym	Deferred Tax Assets Nol State DeferredTaxAssetsNOLState	1086609	usd
CY2021Q4	crym	Deferred Tax Assets Nol State DeferredTaxAssetsNOLState	608703	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6690261	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3244615	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6693634	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3269776	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3373	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	25161	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	25128168	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	10194806	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	24921659	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	31260334	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	16641692	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6363524	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2749613	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	6693634	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	3269776	usd
CY2022	crym	Other Lease Term OtherLeaseTerm	P12M
CY2022	crym	Present Value Of Liabilities Increased Decreased By Business Acquisition PresentValueOfLiabilitiesIncreasedDecreasedByBusinessAcquisition	0	usd
CY2021	crym	Present Value Of Liabilities Increased Decreased By Business Acquisition PresentValueOfLiabilitiesIncreasedDecreasedByBusinessAcquisition	519671	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	0	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	664686	usd
CY2021Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent		usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Noncurrent DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent		usd
CY2021	us-gaap	Gross Profit GrossProfit		usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Provision For Other Losses ProvisionForOtherLosses		usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2022	crym	Payoff Of Cryo Cann Loan Agreement At Closing PayoffOfCryoCannLoanAgreementAtClosing		usd
CY2021	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	crym	Repayment Of Notes Payable Related Parties RepaymentOfNotesPayableRelatedParties		usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2022	us-gaap	Proceeds From Construction Loans Payable ProceedsFromConstructionLoansPayable		usd
CY2022	crym	Repaymentofloanspayablecurrent Repaymentofloanspayablecurrent		usd
CY2022	crym	Repayment Of Seller Note For Acquisition RepaymentOfSellerNoteForAcquisition		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2022	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue		usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment		usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther		usd
CY2021	crym	Deferred Only Adjustment DeferredOnlyAdjustment		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount		usd
CY2022Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent		usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment		usd
CY2022Q4	crym	Deferred Tax Assets Customer Relationships DeferredTaxAssetsCustomerRelationships		usd
CY2022Q4	crym	Deferred Tax Assets Patent DeferredTaxAssetsPatent		usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001533030

Files In Submission

Name	View Source	Status
crym-20221231_cal.xml	Edgar Link	unprocessable
0001213900-23-022859-index-headers.html	Edgar Link	pending
0001213900-23-022859-index.html	Edgar Link	pending
0001213900-23-022859.txt	Edgar Link	pending
0001213900-23-022859-xbrl.zip	Edgar Link	pending
crym-20221231.xsd	Edgar Link	pending
f10k2022ex10-20_cryomasstec.htm	Edgar Link	pending
f10k2022ex31-1_cryomasstec.htm	Edgar Link	pending
f10k2022ex31-2_cryomasstec.htm	Edgar Link	pending
f10k2022ex32-1_cryomasstec.htm	Edgar Link	pending
f10k2022ex32-2_cryomasstec.htm	Edgar Link	pending
f10k2022_cryomasstec.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
crym-20221231_def.xml	Edgar Link	unprocessable
crym-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
crym-20221231_pre.xml	Edgar Link	unprocessable
f10k2022_cryomasstec_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRYM
Cryomass Technologies, Inc. Stock $crym

2023 Q1 Form 10-K Financial Statement

#000121390023022859 Filed on March 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRYM Cryomass Technologies, Inc. Stock $crym

2023 Q1 Form 10-K Financial Statement

#000121390023022859 Filed on March 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRYM
Cryomass Technologies, Inc. Stock $crym